ProSkelia Overview

  • Founded
  • 2002
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 65
Employees
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 3

ProSkelia General Information

Description

Provider of drug discovery and development intended to treat bone diseases. The company's portfolio of technology includes an exclusive program named oestradiol glucoside ("E2G"), which completed a Phase IIa clinical study for the treatment of menopausal symptoms, along with drugs related to the preclinical development and in vivo pharmacology.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 102 route de Noisy
  • 93230 Romainville
  • France
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ProSkelia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ProSkelia‘s full profile, request access.

Request a free trial

ProSkelia Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProSkelia Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ProSkelia‘s full profile, request access.

Request a free trial